Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
Article has an altmetric score of 3

See more details

Referenced in 1 patents
10 readers on Mendeley
  • Article usage
  • Citations to this article (20)

Advertisement

Research Article Free access | 10.1172/JCI114827

A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans.

J H Schiller, B Storer, D M Paulnock, R R Brown, S P Datta, P L Witt, and E C Borden

Department of Human Oncology, University of Wisconsin Clinical Cancer Center, Madison 53792.

Find articles by Schiller, J. in: PubMed | Google Scholar

Department of Human Oncology, University of Wisconsin Clinical Cancer Center, Madison 53792.

Find articles by Storer, B. in: PubMed | Google Scholar

Department of Human Oncology, University of Wisconsin Clinical Cancer Center, Madison 53792.

Find articles by Paulnock, D. in: PubMed | Google Scholar

Department of Human Oncology, University of Wisconsin Clinical Cancer Center, Madison 53792.

Find articles by Brown, R. in: PubMed | Google Scholar

Department of Human Oncology, University of Wisconsin Clinical Cancer Center, Madison 53792.

Find articles by Datta, S. in: PubMed | Google Scholar

Department of Human Oncology, University of Wisconsin Clinical Cancer Center, Madison 53792.

Find articles by Witt, P. in: PubMed | Google Scholar

Department of Human Oncology, University of Wisconsin Clinical Cancer Center, Madison 53792.

Find articles by Borden, E. in: PubMed | Google Scholar

Published October 1, 1990 - More info

Published in Volume 86, Issue 4 on October 1, 1990
J Clin Invest. 1990;86(4):1211–1221. https://doi.org/10.1172/JCI114827.
© 1990 The American Society for Clinical Investigation
Published October 1, 1990 - Version history
View PDF
Abstract

To directly compare clinical side effects and biological response modification, IFN-beta ser, IFN-gamma, or the combination of IFN-beta ser plus IFN-gamma was administered to 21 cancer patients. Each IFN or the combination was given intravenously on days 1, 8, and 15 in varied order. Each IFN and the combination resulted in significant (P less than 0.05) modulation of IFN-induced proteins. IFN-beta ser was more effective than IFN-gamma in enhancing 2-5A synthetase activity (P = 0.001). IFN-gamma was more effective than IFN-beta ser in enhancing serum beta 2 microglobulin expression (P = 0.05) and indoleamine dioxygenase activity, as assessed by decreased serum tryptophan (P = 0.03). The combination enhanced tryptophan catabolism more effectively than IFN-beta ser in a dose-dependent manner (P less than 0.03). IFN-beta ser/IFN-gamma did not potentiate natural killer cells or antibody-dependent cellular toxicity (ADCC). IFN-beta ser/IFN-gamma enhanced monocyte guanylate cyclase activity, as assessed by serum neopterin, more effectively than IFN-gamma alone (P = 0.005). Both IFNs and the combination resulted in increases in HLA class II expression on monocytes. However, no significant difference in the level of induction of HLA DQ and HLA DR expression between IFN-beta ser/IFN-gamma and either IFN-beta ser or IFN-gamma was noted. Although frequency and servity of side effects of IFN-beta ser, IFN-gamma, or the combination were dose related, induction of induced proteins (with exception of influences on tryptophan catabolism) were not a function of dose administered over the 10-fold range. Continued treatment with the combination intravenously three times a week for 4 wk sustained but did not further potentiate, most of the changes in interferon-induced proteins. Thus, IFN-beta ser and IFN-gamma each resulted in effective and essentially equivalent patterns of induction of induced proteins. When combined, however, these IFNs did not result in potentiation of biological response modification in vivo.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1211
page 1211
icon of scanned page 1212
page 1212
icon of scanned page 1213
page 1213
icon of scanned page 1214
page 1214
icon of scanned page 1215
page 1215
icon of scanned page 1216
page 1216
icon of scanned page 1217
page 1217
icon of scanned page 1218
page 1218
icon of scanned page 1219
page 1219
icon of scanned page 1220
page 1220
icon of scanned page 1221
page 1221
Version history
  • Version 1 (October 1, 1990): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

Article has an altmetric score of 3
  • Article usage
  • Citations to this article (20)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 1 patents
10 readers on Mendeley
See more details